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Background: Lipoprotein associated phospholipase A2 (Lp-PLA2) is a novel biomarker for cardiovascular risk
prediction. Whether increased Lp-PLA2 level is associated with re-stenosis after stent-placement is unclear.
Methods: Totally 326 participants eligible for stent-placement were enrolled and divided into two groups according
to baseline Lp-PLA2 levels (named normal and elevated groups). Baseline characteristics and clinical outcomes were
compared between normal and elevated groups. The relationships between Lp-PLA2 and other risk factors with
re-stenosis were evaluated.
Results: Only the between-group difference of Lp-PLA2 was significant (123.2 ± 33.6 ng/mL vs 336.8 ± 85.4 ng/mL,
P < 0.001) while other demographic and clinical characteristics between these two groups were comparable.
Approximately 55.1% and 58.5% of participants in normal and elevated groups presented with acute coronary
syndrome, and the percentage of tri-vessels stenoses was significantly higher in elevated group (40.8% vs 32.1%,
P = 0.016). Nearly 96.0% and 94.0% of participants in normal and elevated Lp-PLA2 groups were placed with drug-
eluting stents, and the others were with bare-metal stents. After 1 year’s follow-up, the incidence of clinical end-
points was comparable (13.3% vs 15.4%, P = 0.172). Nevertheless, the incidence of re-stenosis was marginally higher
in elevated Lp-PLA2 group (8.5% versus 4.6%, P = 0.047). With multivariate analysis, after adjustment for other risk
factors, Lp-PLA2 remained an independent predictor for re-stenosis with a hazard ratio of 1.140. No synergistic effect
between Lp-PLA2 and other risk factors for re-stenosis was found.
Conclusion: Increased Lp-PLA2 level is associated with an increased risk of re-stenosis. Lp-PLA2 assessment may be
useful in predicting subjects who are at increased risk for re-stenosis.
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Atherosclerotic cardiovascular diseases (CAD), in terms
of coronary heart disease (CHD), ischemic stroke and
peripheral vascular disease, are still the leading causes of
morbidity and mortality worldwide [1,2]. Currently, it
has been well documented that inflammatory reaction
plays critical roles on the initiation and progression of
atherosclerosis and CHD [3,4]. Lipoprotein associated* Correspondence: wymai@hotmail.com; HuizhouXiaoc@163.com
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unless otherwise stated.phospholipase A2 (Lp-PLA2), an enzyme excreted by
inflammatory cells such as macrophages, nowadays has
raised many concerns owing to its highly sensitive and
specific features for vascular inflammation [5,6]. Pre-
viously, some basic research show that Lp-PLA2 plays
casual role on atherosclerosis and inhibiting Lp-PLA2
ameliorates vascular inflammation and deters athero-
sclerosis progression [7,8]. Furthermore, some epide-
miological studies and meta-analyses also consistently
show that increased plasma level of Lp-PLA2 is associ-
ated with increased risk of cardiovascular events [9-12].
In light of these findings, Lp-PLA2 has been recognizedLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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risk assessment [13,14].
Currently, percutaneous coronary intervention (PCI) is
the preferred choice for patients with acute myocardial
infarction or with significant coronary artery stenoses.
Nevertheless, despite dual anti-platelet and intensive sta-
tins therapy, the incidence of re-stenosis after stent place-
ment is still high [15,16]. Therefore, identifying a specific
and sensitive biomarker for predicting re-stenosis is of
paramount importance. Owing to the significant and un-
equivocal implications of Lp-PLA2 on the initiation and
progression of atherosclerosis and CAD, we speculated
that increased plasma level of Lp-PLA2 at baseline might
contribute to re-stenosis in patients with stent placement.
If finally corroborated, we believed that in the future lo-
wering Lp-PLA2 level with its specific antagonist would
definitely reduce the risk of re-stenosis and doubtless im-
prove the outcomes of patient with CAD.
Method
Study population and protocol
Current study was started in September of 2011 and en-
ded in September of 2012. All participants were without
previous history of atherosclerotic cardiovascular dis-
eases. After angiographic evaluation, patients diagnosed
as significant CHD and eligible for stent-placement were
enrolled after written informed consent was obtained.
Baseline demographic and clinical characteristics includ-
ing traditional risk factors and laboratory results were
collected. All participants were followed-up for 1 year
via outpatient visit or telephone contact for detecting
the first episode of pre-specified clinical outcomes.
Routine laboratory parameters and Lp-PLA2
measurements
Fasting blood samples were drawn by veni-puncture in
the morning. Measurements of routine laboratory pa-
rameters in current study were consistent to previous
study report unless otherwise mentioned [17]. Plasma
level of Lp-PLA2 was detected with commercial Lp-
PLA2-ELISA kit (PLAC test; supplied by dia Dexus Inc,
South San Francisco, California). All the procedures were
performed according to the manufactures’ instructions.
Based on previous recommendation [18], plasma Lp-
PLA2 level less than 200 ng/mL is defined as within
normal range, while equal or higher than 200 ng/mL is
recognized as elevation. All participants were divided into
two groups on the basis of the plasma level of Lp-PLA2.
Clinical outcomes assessments post-stent placement
Clinical outcomes were defined as cardiovascular related
death, nonfatal myocardial infarction, nonfatal ischemic
stroke, and re-stenosis (> 50% stenosis of target lesion)
by angiographic examination. Comparisons of clinicaloutcomes were conducted between groups with normal
or elevated plasma levels of Lp-PLA2 during the 1 year’s
follow-up. Risk factors for re-stenosis after 1 year’s follow-
up were also evaluated.
Statistical analysis
Continuous variable was presented as mean ± SD or me-
dian appropriately, and compared by the Student’s t-test
when data was normally distributed, otherwise com-
pared by Wilcoxon rank-sum test. Categorical data was
showed as percentage and compared by χ2 test. Univari-
ate and multivariate Cox proportional hazard regression
were used to evaluate the associations between baseline
demographic and clinical characteristics and incidence
of re-stenosis after 1 year’s follow-up. Variables with p
values < 0.10 were entered into multivariable model and
variables with p values < 0.10 were stayed in the model.
Synergistic effects between other risk factors and Lp-
PLA2 for re-stenosis were also evaluated. Statistical ana-
lyses were performed by using SPSS software version
16.0 (SPSS, Inc., Chicago, Illinois). A value of p <0.05 was
considered significant.
Results
Baseline demographic and clinical characteristics of
participants
A total of 326 participants were enrolled in our current
study, and accordingly, were divided into two groups
on the basis of baseline plasma levels of Lp-PLA2. As
presented in Table 1, only the difference of plasma Lp-
PLA2 level between the normal and elevated groups
achieved statistical significance. Male patients were pre-
dominant and accounted for 66.3% and 65.4% in each
group, respectively. More than 50.0% of patients in each
group have a history of hypertension. Each group had
nearly 20% of patients with diabetes mellitus, and 29
(85.3%) patients in normal Lp-PLA2 group and 20
(83.3%) patients in elevated Lp-PLA2 group were treated
with insulin and the rest (14.7% vs 16.7%, P = 0.283)
were treated with sulfonylureas. More than 40.0% of
participants in both groups have a family history of
atherosclerotic cardiovascular diseases. Notably, in both
groups, baseline levels of Hs-CRP were increased, and no
significant differences were found across other risk factors
such as total cholesterol, LDL-C, HDL-C and Lp(a) levels
in both groups.
Angiographic characteristics and clinical presentations of
participants
As shown in Table 2, participants in Lp-PLA2 elevated
group more frequently presented with emergency condi-
tions such as unstable angina and acute myocardial infarc-
tion than the normal Lp-PLA2 group (58.5% vs 55.1%).
Moreover, the percentage of three vessels stenoses was






Age (years) 57.4 ± 11.6 58.3 ± 13.2 0.115
Male (%) 130 (66.3) 85 (65.4) 0.172
Ever smoking (%) 103 (52.6) 71 (54.6) 0.168
HTN (%) 105 (53.6) 72 (55.4) 0.138
DM (%) 40 (20.4) 28 (21.5) 0.144
Family history (%) 82 (41.8) 58 (44.6) 0.126
BMI (Kg/m2) 25.4 ± 2.7 25.6 ± 2.2 0.278
CHOL (mmol/L) 4.64 ± 1.08 4.78 ± 1.12 0.389
LDL-C (mmol/L) 2.46 ± 0.79 2.68 ± 0.93 0.175
HDL-C (mmol/L) 1.08 ± 0.36 1.07 ± 0.33 0.405
Log TG (mmol/L) 0.17 ± 0.22 0.15 ± 0.21 0.141
Lp(a) (mg/dL) 27.6 ± 8.4 32.4 ± 10.5 0.062
CREA (umol/L) 93.5 ± 36.4 97.4 ± 32.8 0.804
BUN (mmol/L) 6.7 ± 1.3 7.1 ± 1.6 0.628
Uric acid (umol/L) 394.5 ± 122.5 377.6 ± 112.8 0.767
Hs-CRP (mg/L) 4.11 ± 0.92 4.07 ± 0.86 0.276
Lp-PLA2 (ng/mL) 123.2 ± 33.6 336.8 ± 85.4 <0.001
LVEF (%) 65.4 ± 12.6 63.8 ± 10.2 0.446
FS (%) 28.5 ± 3.3 27.2 ± 3.6 0.308
Anti-DM (%) 34 (85.0) 24 (85.7) 0.147
Anti-HTN (%) 98 (93.3) 67 (93.1) 0.325
Denote: HTN = hypertension, DM = diabetes mellitus, BMI = body mass index,
CHOL = total cholesterol, TG = triglyceride, Lp(a) = lipoprotein(a), CREA =
creatinine, BUN = blood uria nitrogen, LVEF = left ventricular ejection fraction,
FS = fraction shortening.
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group (40.8% vs 32.1%).
Clinical outcome evaluation after 1 year’s follow-up
Approximately 96.0% (188) and 94.0% of participants
(122) in normal and elevated Lp-PLA2 groups were placed
with drug-eluting stents (DES), and the others were with
bare-metal stents (BMS). During 1 year’s follow-up, all







UA (%) 75(38.3) 56(43.1) 0.042
AMI (%) 33(16.8) 20(15.4) 0.177
SA (%) 88(44.9) 54(41.5) 0.068
Tri-vessels (%) 63(32.1) 53(40.8) 0.016
Left main (%) 38(19.4) 24(18.5) 0.183
Denote: UA = unstable angina, AMI = acute myocardial infarction, SA = stable
angina.plus clopidogrel) and statins (atorvastatin or rosuvastatin)
therapies. Other medications such as beta-receptor bloc-
kers, angiotensin-converting enzyme (ACE) inhibitor or
angiotensin receptor blocker, and medications for hyper-
tension or glucose control were prescribed accordingly,
and no between-group differences were found. The inci-
dence of clinical outcomes was comparable between nor-
mal and elevated Lp-PLA2 groups (13.3% versus 15.4%,
P = 0.172, see Table 3). Moreover, each pre-specified out-
come was further evaluated and only the incidence of re-
stenosis was slightly but significantly higher in elevated
Lp-PLA2 group than that of normal Lp-PLA2 group
(8.5% vs 4.6%, P = 0.047).
Univariate and multivariate analysis for incidence of
re-stenosis after 1 year’s follow-up and evaluation of
synergistic effect
For further evaluating the value of each parameter for
the prediction of re-stenosis after 1 year’s stent-placement,
univariate and multivariate analyses were conducted. As
showed in Table 4, several variables were found associated
with re-stenosis after 1 year’s stent-placement with univar-
iate analysis. However, with multivariate analysis, after ad-
justment for variables such as age, smoking, hypertension,
total cholesterol, Lp(a), Hs-CRP, anti-platelet and medica-
tions for hypertension, only diabetes mellitus, LDL-C and
Lp-PLA2 were found increasing hazard ratio for re-
stenosis, whereas statins and medications for diabetes
mellitus were found beneficial for reducing the incidence
of re-stenosis (See Table 5). Synergistic effects between
Lp-PLA2 and other risk factors for re-stenosis were evalu-
ated by Cox proportional hazard regression and all values
of P were higher than 0.05.
Discussion
Importantly, our current study shows that increased plas-
ma level of Lp-PLA2 at baseline is associated with an in-
creased risk for re-stenosis after 1 year’s stent placement.
Moreover, patients with increased Lp-PLA2 level more
frequently present with urgent situations such as unstable









6 (3.1) 3 (2.3) 0.138
Nonfatal MI (%) 5 (2.6) 3 (2.3) 0.216
Nonfatal Stroke (%) 6 (3.1) 3 (2.3) 0.138
Re-stenosis (%) 9 (4.6) 11 (8.5) 0.047
Total (%) 26 (13.3) 20 (15.4) 0.172
Denote: MI = myocardial infarction.
Table 4 Univariate analysis for re-stenosis
Variables Hazard ratio (95% CI) P value
Age 1.043 (0.906–1.083) 0.091
Male 1.052 (0.922–1.074) 0.106
Smoking 1.078 (1.003–1.125) 0.015
HTN 1.106 (1.018–1.276) 0.021
DM 1.145 (1.056–1.303) 0.007
Family history 1.008 (0.914–1.022) 0.108
BMI 1.002 (0.967–1.005) 0.455
CHOL 1.089 (0.953–1.117) 0.075
LDL-C 1.227 (1.104–1.420) <0.001
HDL-C 0.895 (0.806–1.007) 0.303
TG 1.007 (0.926–1.011) 0.436
Lp (a) 1.103 (1.048–1.166) 0.014
CREA 1.012 (0.915–1.017) 0.344
BUN 1.005 (0.933–1.009) 0.428
Uric acid 1.017 (0.908–1.032) 0.447
Hs-CRP 1.168 (1.109–1.254) <0.001
Lp-PLA2 1.233 (1.114–1.387) <0.001
LVEF 1.017 (0.908–1.032) 0.160
FS 1.011 (0.933–1.019) 0.174
Anti-platelet 0.826 (0.801–0.944) 0.022
Statins 0.778 (0.723–0.806) <0.001
Medications for HTN 0.909 (0.886–1.005) 0.096
Medications for DM 0.845 (0.817–0.896) 0.018
Denote: CI = confidence interval.
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ly associated with a higher incidence of plaque rupture
and major adverse events [19,20]. Additionally, our study
also reveals that although a vast majority of patients pre-
sent with Hs-CRP elevation, increased Hs-CRP level at
baseline is not associated with re-stenosis after adjustment
for other risk factors, and no synergistic effects between
Lp-PLA2 and other risk factors for re-stenosis is found in
current study.
Notably, in the past decades, the outcomes of patients
with acute coronary syndrome have been significantly
improved by stent placement, and with its excellentTable 5 Multivariate analysis for re-stenosis
Variables Hazard ratio (95% CI) P value
DM 1.078 (1.014–1.117) 0.023
LDL-C 1.165 (1.074–1.205) 0.008
Lp-PLA2 1.140 (1.068–1.195) 0.017
Statins 0.806 (0.788–0.865) 0.032
Medications for DM 0.837 (0.802–0.925) 0.037features of less invasive and highly efficient, PCI has
become the principal therapy for patients with significant
CHD [21-23]. However, the incidence of re-stenosis after
PCI is still high in spite of prolongation of dual anti-
platelet therapy and intensive statin treatment [15,24].
Many mechanisms have been identified responsible for
this phenomenon. For example, endothelial dysfunction
and activation, smooth muscle cells migration and pro-
liferation, as well as continuous vascular inflammation
have been demonstrated that individually and/or sim-
ultaneously contribute to in-stent re-stenosis [25,26].
Accordingly, Lp-PLA2 is an enzyme predominantly
produced by leukocytes within atherosclerotic plaques
and then excretes into circulation system [27,28]. It has
now been well documented that plasma level of Lp-
PLA2 is highly correlated with the concentration of
Lp-PLA2 within the plaques [29]. Therefore, evaluating
plasma level of Lp-PLA2 could accurately and promptly
reflect the severity of vascular inflammation. Owning to
its value of adding prognostic information to traditional
risk evaluation algorithm, measurement of Lp-PLA2 has
been recommended to patients with moderate or high
cardiovascular risk [18,30]. However, whether increased
plasma level of Lp-PLA2 is associated with an increased
risk of re-stenosis after stent-placement is still unclear.
For example, the study conducted by Moldoveanu and
colleagues showed that there was no significant differ-
ence of baseline level of Lp-PLA2 in patients with and
without re-stenosis after PCI [31]. Nevertheless, the re-
sult in our current study indicated that increased base-
line level of Lp-PLA2 portended an increased risk of
re-stenosis after 1 year’s follow-up. To our best know-
ledge, there might be some mechanisms contributing to
this discrepancy. In the first place, the protocols of these
two studies are quite different. In the study conducted
by Moldoveanu et al., they divided patients into two
groups according to the end-point in terms of with or
without in-stent re-stenosis. While in our study, patients
were assigned into normal and elevated Lp-PLA2 groups
according to their baseline levels. Secondary, the dura-
tion of follow-up in the former study was only 6 months,
while the patients in our study were followed-up for
1 year. Thirdly, the smaller sample size of Moldoveanu’s
study might also be a potential reason for the negative
finding. In light of the mechanisms associated with re-
stenosis as mentioned above, we believed that the com-
plex roles Lp-PLA2 plays on vessel walls might in part ex-
plain our findings. Pathophysiologically, after engulfed by
macrophages, oxidative-LDL would be degraded into two
major substrates, named lyso-phosphotidylcholine (Lyso-
PC) and oxidized non-esterified fatty acids (oxNEFAs), by
Lp-PLA2. Accordingly, Lyso-PC and oxNEFAs have po-
tent effects in recruiting inflammatory cells, promoting
platelets activation and aggregation, impairing endothelial
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eration and migration which subsequently lead to neoin-
tima formation and re-stenosis [32-34]. Taken together, it
was reasonable to speculate that increased plasma level of
Lp-PLA2 was associated with higher risk of re-stenosis.
Nevertheless, the study conducted by Turunen and col-
leagues showed that local adenovirus-mediated Lp-PLA2
gene transfer resulted in a significant reduction in neo-
intima formation in balloon-denuded rabbit aorta [35].
However, the pathophysiology of aorta denudation by bal-
loon was somewhat, if not completely, different from that
of vascular inflammation inducing by hyperlipidemia and
endothelial dysfunction and activation. Furthermore, a
large number of clinical studies have consistently demon-
strated the positive relationship between increased plas-
ma level of Lp-PLA2 and adverse clinical outcomes
[8,9,11,20]. Additionally, as stent placement may stimulate
local inflammatory reaction and up-regulate inflammatory
cytokines such as tumor necrosis factor-alpha expression,
which in turn leads to platelet activating factor and Lp-
PLA2 correspondingly increase. However, since only
baseline Lp-PLA2 level has been measured, our study
was impossible to make any conclusion that whether
the change of platelet activating factor and Lp-PLA2
after stent-placement would also have significant effects
on re-stenosis. Furthermore, since the percentages of
drug-eluting stent and bare-metal stent placement in
the normal and elevated groups were comparable, any
bias related to stent-placement might also be excluded. In
the future, conducting a prospective research to investi-
gate whether reducing Lp-PLA2 level could decrease the
risk of re-stenosis would definitely be a milestone with re-
gard to the new era of CAD therapy.
On the other hand, at the very beginning, Lp-PLA2
was considered as a cardio-protective factor due to its
effects on degrading platelet activating factor, a potent
substrate in enhancing vascular inflammation and impai-
ring cardiac function [36]. Nevertheless, since the posi-
tive relationship between Lp-PLA2 level and increased
CVD risk has been firstly reported in WOSCOPS study
in 2000 [37], many studies thereafter have consistently
corroborated the detrimental effects of Lp-PLA2 on car-
diovascular system [8,38,39]. Currently, the results from
our study also indicated that patient with increased Lp-
PLA2 level appeared to present more severe and urgent
condition than that with normal Lp-PLA2 level, which
might be partially explained by the adverse effects (ex-
panding necrotic lipid core and thinning fibrous cap)
Lp-PLA2 imposes on vessel walls [8,40]. The higher per-
centage of patients with three vessels stenoses in elevated
Lp-PLA2 group might also partially reflect the adverse ef-
fects Lp-PLA2 exerts on atherogenesis and progression.
Thirdly, due to the production of inflammatory cyto-
kines such as interleukin-6 tumor necrosis factor-alphaand platelet activating factor from adipose tissues, obe-
sity is considered as one of the major risk factor for car-
diovascular events such as in-stent re-stenosis [41,42].
Interestingly, previous one study showed that increased
Lp-PLA2 might compensate for the adiposity-associated
increases in inflammatory and oxidative burden [43].
Therefore, it might be reasonable to speculate that in
patients with obesity, the incidence of re-stenosis in
higher Lp-PLA2 level group might be lower than the
lower Lp-PLA2 group. However, in our current study,
no significant difference of incidence of re-stenosis was
found in obese patients with normal and increased Lp-
PLA2 level (33.3% vs 36.4%, P = 0.208).
Finally, since a vast majority of participants in current
study were with increased level of Hs-CRP (>3 mg/L),
we therefore further evaluated the relationship between
Hs-CRP level and re-stenosis. With univariate analysis,
Hs-CRP appeared to be a potential predictor for re-
stenosis. Nevertheless, after adjustment for other risk
factors, Hs-CRP did not remain independently associated
with re-stenosis, which was consistent with previous stud-
ies [44,45], in which increased Hs-CRP level before PCI
were not associated with in-stent re-stenosis. We believed
that this negative finding might be partially due to the un-
specific characteristic of Hs-CRP, with respect to Hs-CRP
elevation could be confounded by other diseases such as
latent and modest infection [46,47]. Contrary to Hs-CRP,
Lp-PLA2 still remained an independent predictor for re-
stenosis after adjustment for other risk factors (hazard ra-
tio: 1.140, 95% confidence interval: 1.068-1.195), which we
believed was predominantly due to its high specificity for
vascular inflammation in the setting of atherosclerotic car-
diovascular diseases [6,14]. In order to explore any syner-
gistic effect between Lp-PLA2 and other risk factors for
re-stenosis, Cox proportional hazard regression were per-
formed and no significant synergism was found which we
considered might be partially ascribed to the relatively
small sample size of current study and future study is war-
ranted to further investigate whether any synergistic effect
exists between traditional risk factor and Lp-PLA2 for re-
stenosis after stent-placement.
Conclusion
The results of our study indicate that increased plasma
level of Lp-PLA2 at baseline is associated with increased
risk of re-stenosis after 1 year’s stent-placement, and
measurement of Lp-PLA2 may be helpful and useful for
identifying subjects who are at an increased risk for re-
stenosis. Future study is warranted to investigate whether
decreasing plasma level of Lp-PLA2 with specific antago-
nist will reduce the incidence of re-stenosis.
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